4/16
04:58 pm
uncy
Unicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Unicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript [Seeking Alpha]
4/9
11:53 am
uncy
Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm
Low
Report
Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm
4/9
07:05 am
uncy
Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Medium
Report
Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
4/6
08:43 am
uncy
Unicycive Therapeutics (UNCY) had its price target lowered by Benchmark Co. from $21.00 to $15.00. They now have a "speculative buy" rating on the stock.
Medium
Report
Unicycive Therapeutics (UNCY) had its price target lowered by Benchmark Co. from $21.00 to $15.00. They now have a "speculative buy" rating on the stock.
4/2
10:14 am
uncy
Unicycive Therapeutics (UNCY) had its price target lowered by Guggenheim from $46.00 to $40.00. They now have a "buy" rating on the stock.
Low
Report
Unicycive Therapeutics (UNCY) had its price target lowered by Guggenheim from $46.00 to $40.00. They now have a "buy" rating on the stock.
3/30
07:15 am
uncy
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
3/30
07:05 am
uncy
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update
Medium
Report
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update
3/30
06:20 am
uncy
Unicycive Therapeutics (UNCY) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
High
Report
Unicycive Therapeutics (UNCY) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
2/19
08:03 am
uncy
Unicycive Therapeutics (NASDAQ:UNCY) is now covered by analysts at Westpark Capital. They set a "buy" rating on the stock.
Low
Report
Unicycive Therapeutics (NASDAQ:UNCY) is now covered by analysts at Westpark Capital. They set a "buy" rating on the stock.
2/4
07:05 am
uncy
Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit
Medium
Report
Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit
1/29
04:16 pm
uncy
Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile [Seeking Alpha]
High
Report
Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile [Seeking Alpha]
1/29
09:15 am
uncy
UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
Medium
Report
UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
1/29
07:31 am
uncy
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission [Yahoo! Finance]
Medium
Report
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission [Yahoo! Finance]
1/29
07:05 am
uncy
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
Medium
Report
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission